EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+5.4%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.5B
AUM Growth
+$2.5B
(-14%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-5.91%
Top 10 Holdings %
Top 10 Hldgs %
69.34%
Holding
73
New
8
Increased
7
Reduced
9
Closed
16
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$93.6M |
| 2 |
uniQure
QURE
|
$60M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$56.4M |
| 4 |
Zymeworks
ZYME
|
$23.3M |
| 5 |
Xencor
XNCR
|
$18.7M |
Top Sells
| 1 |
KLRS
Kalaris Therapeutics, Inc. Common Stock
KLRS
|
$105M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$51.5M |
| 3 |
Viridian Therapeutics
VRDN
|
$44.6M |
| 4 |
Nuvation Bio
NUVB
|
$44M |
| 5 |
Vaxcyte
PCVX
|
$40.3M |
Sector Composition
| 1 | Healthcare | 99.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $379M | 14.35% | 11,890,843 | – | – |
|
|
2
Zymeworks
ZYME
$1.12B
| $220M | 8.32% | 15,028,079 +1,590,606 | +12% | +$23.3M |
|
3
Crinetics Pharmaceuticals
CRNX
$2.92B
| $219M | 8.29% | 4,288,120 | – | – |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $210M | 7.95% | 1,706,469 | – | – |
|
5
Prothena Corp
PRTA
$441M
| $160M | 6.07% | 11,584,280 | – | – |
|
|
6
Xencor
XNCR
$580M
| $141M | 5.34% | 6,144,767 +814,351 | +15% | +$18.7M |
|
7
Arvinas
ARVN
$568M
| $129M | 4.88% | 6,726,491 | – | – |
|
8
AnaptysBio
ANAB
$569M
| $104M | 3.94% | 7,873,448 +78,452 | +1% | +$1.04M |
|
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $93.6M | 3.54% | +770,000 | New | +$93.6M |
|
10
Janux Therapeutics
JANX
$1.37B
| $78.7M | 2.98% | 1,469,818 | – | – |
|
|
11
uniQure
QURE
$896M
| $60M | 2.27% | +3,400,000 | New | +$60M |
|
|
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
| $56.4M | 2.13% | +1,560,000 | New | +$56.4M |
|
13
CRISPR Therapeutics
CRSP
$4.71B
| $54.7M | 2.07% | 1,389,276 | – | – |
|
14
Immunome
IMNM
$828M
| $41.2M | 1.56% | 3,879,415 | – | – |
|
|
TECX
15
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $39.2M | 1.48% | 849,143 | – | – |
|
16
Tango Therapeutics
TNGX
$747M
| $32.8M | 1.24% | 10,630,736 -2,700,000 | -20% | -$8.34M |
|
|
THRD
17
DELISTED
Third Harmonic Bio
THRD
| $32.7M | 1.24% | 3,182,444 | – | – |
|
18
Kura Oncology
KURA
$686M
| $31M | 1.17% | 3,557,269 -2,249,602 | -39% | -$19.6M |
|
19
Neurogene
NGNE
$264M
| $29.1M | 1.1% | 1,271,342 | – | – |
|
20
Oric Pharmaceuticals
ORIC
$994M
| $27.6M | 1.04% | 3,418,068 | – | – |
|
21
Eton Pharmaceutcials
ETON
$464M
| $24.4M | 0.92% | 1,829,603 +1,263,528 | +223% | +$16.8M |
|
|
MBX
22
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $23.2M | 0.88% | 1,259,273 +83,464 | +7% | +$1.54M |
|
23
Madrigal Pharmaceuticals
MDGL
$9.76B
| $23.1M | 0.87% | 75,000 | – | – |
|
24
Voyager Therapeutics
VYGR
$186M
| $22.2M | 0.84% | 3,917,546 | – | – |
|
25
Neumora Therapeutics
NMRA
$280M
| $22M | 0.83% | 2,071,450 | – | – |
|